PMID: 9180349Jan 1, 1997Paper

Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes

Life Sciences
C IribarneF Berthou

Abstract

Buprenorphine is a long acting analgesic of the opiate family. Recently, it has been proposed for the opioid dependency treatment at a large scale. The drug is extensively metabolized by the hepatic cytochrome P450 in man, yielding a N-dealkylated metabolite, norbuprenorphine. The specific forms of P450 involved in this oxidative N-demethylation were examined in a panel of 18 human liver microsomal preparations previously characterized with respect to their P450 contents. Buprenorphine was N-dealkylated with an apparent Km of 89 +/- 45 microM (n = 3). The metabolic rates were 3.46 +/- 0.43 nmol/(min x mg of protein). This metabolic pathway was strongly correlated with 6 catalytic activities specific to P450 3A4 and with the immunodetectable P450 3A content of liver microsomal samples (r = 0.87). Buprenorphine metabolism was 62-71% inhibited by three mechanism-based inhibitors (TAO, erythralosamine, gestodene), by nifedipine as competitive inhibitor (Ki = 129 microM) and by ketoconazole 0.6 microM (25% residual activity), all these inhibitors specific to P450 3A. Among 10 heterologously expressed P450s tested, only P450 3A4 was able to dealkylate buprenorphine with a turnover number of 9.6 min(-1). Morever, this catalytic activi...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Jul 1, 1990·Chemical Research in Toxicology·F P Guengerich
Sep 1, 1988·Clinical Pharmacology and Therapeutics·D S WeinbergK M Foley
Jan 1, 1988·Clinical Pharmacology and Therapeutics·W K BickelR E Johnson
Oct 1, 1985·Biochemical Pharmacology·P BeauneJ E Gielen
Jul 1, 1983·Clinical Pharmacokinetics·R E BullinghamR A Moore
Feb 8, 1980·Science·N K Mello, J H Mendelson
Dec 15, 1995·Toxicology·A P LiA Rasmussen
Jun 1, 1996·Pharmacogenetics·V CarrièreI de Waziers
Aug 1, 1961·The Biochemical Journal·G N WILKINSON
Nov 18, 2006·Clinical Chemistry·Xavier BossuytKris De Boeck

❮ Previous
Next ❯

Citations

Apr 22, 2008·Molecular Diagnosis & Therapy·Yongfang LiSiamak Davani
Jan 20, 2005·European Journal of Clinical Pharmacology·Yan Chang, David E Moody
Apr 7, 2010·International Journal of Legal Medicine·Anne-Laure Pelissier-AlicotGeorges Leonetti
Nov 9, 2006·Current HIV/AIDS Reports·Paula J Lum, Jacqueline Peterson Tulsky
Feb 7, 2001·Life Sciences·R B IbrahimD J Edwards
May 10, 2003·Drug and Alcohol Dependence·C Nora Chiang, Richard L Hawks
May 10, 2003·Drug and Alcohol Dependence·Rolley E JohnsonLeslie Amass
May 8, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·A Polettini, M A Huestis
Mar 30, 2002·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Larry C Wienkers
Jul 23, 2010·Journal of Psychoactive Drugs·Donald R Wesson, David E Smith
Nov 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elinore F McCance-Katz
Nov 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R Douglas BruceGene D Morse
Nov 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elinore F McCance-KatzPetrie M Rainey
Oct 21, 2011·Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine·Kenneth F IlettAnne E Bartu
Feb 21, 2013·Journal of Analytical Toxicology·Thomas BergDag Helge Strand
Jun 1, 2007·Journal of Addiction Medicine·Peggy ComptonCharles Charuvastra
Mar 11, 2010·Therapeutic Drug Monitoring·Marta ConcheiroMarilyn A Huestis
May 5, 1998·Fundamental & Clinical Pharmacology·C IribarneF Berthou
Sep 24, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·David E MoodyCurtis J Omiecinski
May 30, 2002·Biological & Pharmaceutical Bulletin·Ken UmeharaGohachiro Miyamoto
Feb 5, 2002·Clinical Pharmacokinetics·Jorn LotschGerd Geisslinger
Jun 22, 2005·Clinical Pharmacokinetics·Alexander Elkader, Beth Sproule
Feb 22, 2011·Pharmacogenomics·Markus R Meyer, Hans H Maurer
Nov 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Valerie A GruberElinore F McCance-Katz
Nov 26, 2009·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Eirin Bakke, Liliana Bachs
Mar 29, 2011·The American Journal of Drug and Alcohol Abuse·R Douglas BruceGerald H Friedland
Feb 6, 2008·Journal of Substance Abuse Treatment·Hendree E JonesGabriele Fischer
Jul 24, 2007·Drug and Alcohol Dependence·Elinore F McCance-KatzPetrie M Rainey
Jun 24, 2008·European Journal of Pain : EJP·Hans G Kress
Mar 21, 2012·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Anne E BartuDale Hamilton
Nov 19, 2011·British Journal of Clinical Pharmacology·Eloise A GelstonAndrew A Somogyi
Feb 6, 2010·The American Journal on Addictions·Elinore F McCance-KatzPetrie M Rainey
Feb 20, 2014·Journal of Gastroenterology and Hepatology·Jeremy P DwyerAmanda Nicoll
Sep 17, 2004·Biochemical and Biophysical Research Communications·Gilly Regev-ShoshaniZohar Kerem

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.